Dr. Anthony Fauci of the U.S. National Institutes of Health (NIH) called the early results "some very good news." He said the new drugs "...may be able to improve the survival of people with Ebola." The NIH helped support the research.
美国国立卫生研究院的安东尼·福奇称早期试验结果是“一些非常好的消息。”他说这些新药物“可能能够改善埃博拉患者的存活率。”美国国立卫生研究院协助支持了这项研究。

The findings come from a study of four different drugs that started in November of last year. But an independent monitoring group recommended last week that the study be ended early. The group recommended that all new patients should receive either of the two drugs that showed the best results.
这一结果出自去年11月开始的对四种不同药物进行的研究。但是一家独立监测组织上周建议提前结束这项研究。该组织建议所有新增患者应该使用两种显示出最佳疗效的药物中的一种。

The drugs are antibodies that work by blocking the virus in the body. One drug, REGN-EB3, is made by Regeneron Pharmaceuticals. The other, mAb114, was developed by the U.S. National Institutes of Health (NIH). Patients receiving these two drugs "had a greater chance of survival compared to those" receiving the other two drugs, the group found.
这些药物是通过阻断体内病毒起效的抗体。其中一种名为REGN-EB3的药物是由新泽西再生元制药公司所制。另一种名为mAb114的药物是由美国国立卫生研究院研制。该组织发现，与接受另两种药物治疗的患者相比，接受这两种药物治疗的患者的存活机会更大。

An experimental vaccine is also showing signs of effectiveness against the virus.
一种实验性疫苗也显示出对该病毒有效的迹象。

How were the drugs tested?
这些药物如何测试？

The research was designed to test the effectiveness of the drugs on as many as 725 people infected with the Ebola virus in North Kivu and Ituri provinces. An outbreak of Ebola in those parts of the DRC has killed more than 1,800 people since August 2018.
这项研究旨在验证这些药物对北基伍省和伊图里省多达725名埃博拉病毒感染者的有效性。自2018年8月以来，刚果民主共和国的埃博拉病毒爆发已经造成1800多人死亡。

Ebola, a kind of hemorrhagic fever, has a very high rate of mortality. Dr. Michael Ryan of the World Health Organization said about 75 percent of those who become infected and receive no special care die.
埃博拉是一种死亡率很高的出血热。世界卫生组织的迈克尔·瑞恩博士表示，没有接受特殊治疗的感染者的死亡率在75%左右。

But the recent study found that less than one-third of patients who were infected died when they took the two new drugs. Those patients who had low levels of the virus in their blood had even better results.
但是这项最新研究发现，感染者服用这两种新药后的死亡率不到1/3。那些血液中病毒水平较低的患者疗效更好。

Among people who sought treatment early, the mortality rate was 6 percent for REGN-EB3 and the rate for mAb114 was 11 percent.
在早期寻求治疗的患者当中，服用REGN-EB3药物的死亡率只有6%，mAb114药物的死亡率只有11%。

Dr. Ryan of the WHO said he hoped the results would persuade more patients to seek care as soon as symptoms appear. "Getting people into care more quickly is absolutely vital," he said.
世卫组织的瑞恩表示，他希望这些研究结果可以说服更多患者在出现症状后立即寻求治疗。他说：“让人们更早接受治疗绝对是至关重要的。”

However, treating the disease is made more difficult because the affected areas of the eastern DRC face ethnic conflict.
然而，由于刚果民主共和国东部疫区面临种族冲突，因此治疗这种疾病变得更加困难。

Jean-Jacques Muyembe, director general of the National Institute of Biomedical Research in DRC, helped lead the study. He said, "From now on, we will no longer say that Ebola is incurable."
刚果民主共和国国家生物医学研究所所长让-雅克·穆延贝协助领导了这项研究。他说：“从现在开始，我们再不会说埃博拉是无法治愈的啦！”